CPhI and Informa Pharma Intelligence conclude 3rd Biopharma Conclave
The conclave drew insights on biologics, cell and gene therapy, vaccines and biosimilars
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Biosimilars
A Superstar marriage?
Chandru Chawla, a pharma veteran, opines that Biocon and SII coming together is a milestone event in the evolution of Indian…
Cipla takes deal route with Alvotech to enter Australian autoimmune biosimilars market: GlobalData
On March 2, 2021, Cipla Gulf and Alvotech expanded their partnership to market and distribute four biosimilars; aflibercept…
Mylan-UpJohn merger as Viatris provides opportunity to focus on biosimilar launch and uptake
Following the news that the European Medicines Agency (EMA) has approved Kixelle, Biocon/Mylan’s biosimilar of Novo Nordisk’s…
Abu Dhabi firm, ADQ invests Rs 555 crores in Biocon Biologics
Biocon Biologics had raised over $255 million from global investors from Jan to Nov 2020
Xentria gets US FDA orphan drug designation for XTMAB-16 in sarcoidosis
The company is focused on developing novel biologics and biosimilars
Biocon Biologics gets Rs 1, 125 cr capital injection from Goldman Sachs
Goldman Sachs will be issued Optionally Convertible Debentures at a post money equity valuation of $3.94 billion
Informing payers and patients of biological therapy advantages can strengthen biosimilars market
Patients are unaware of the cost savings and payers are unclear if they can replace the reference biologics with the biosimilar…
Cadila Pharma launches Cadalimab (adalimumab biosimilar) for India
It is used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis
Biocon Biologics to get Rs 225 cr from Tata Capital Growth Fund for 0.85 per cent equity stake
Post the completion of this transaction, Biocon will hold 95.25 per cent stake in Biocon Biologics